title: Differential regulation of the low affinity Fc receptor for IgE (Fc epsilon R2/CD23) and the IL-2 receptor (Tac/p55) on eosinophilic leukemia cell line (EoL-1 and EoL-3).
abstract: Two types of activation Ag, low affinity FcR for IgE (Fc epsilon R2)/CD23 and IL-2R (Tac/p55), were expressed and differently regulated on human eosinophilic leukemia cell lines (EoL-1 and EoL-3). Because the binding of IgE on EoL-3 cells was completely inhibited by H107 (anti-Fc epsilon R2/CD23 mAb) but not by irrelevant mAb, essentially all the low affinity Fc epsilon R2 on EoL-3 seemed to be the Fc epsilon R2/CD23 molecules. Both IL-4 and IFN-gamma enhanced the surface expression of Fc epsilon R2, whereas IL-1, IL-2, and IL-5 showed no effects, as determined by surface staining with anti-Fc epsilon R2 antibody (H107). In contrast to Fc epsilon R2 up-regulation, IL-4 and IFN-gamma showed a differential effect on the regulation of IL-2R (Tac/p55). Whereas IFN-gamma up-regulated the receptor expression of IL-2R/Tac, IL-4 did not. The result suggests that these lymphokines are involved in the different aspects of the activation pathway of the eosinophils. The possible role of Fc epsilon R2 and IL-2R on the function of eosinophils in allergic reaction is discussed.
authors.affiliation: Institute for Immunology, Faculty of Medicine, Kyoto University, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Hosoda
authors.forename: S
authors.initials: S
authors.lastname: Makino
authors.forename: T
authors.initials: T
authors.lastname: Kawabe
authors.forename: Y
authors.initials: Y
authors.lastname: Maeda
authors.forename: S
authors.initials: S
authors.lastname: Satoh
authors.forename: M
authors.initials: M
authors.lastname: Takami
authors.forename: M
authors.initials: M
authors.lastname: Mayumi
authors.forename: K
authors.initials: K
authors.lastname: Arai
authors.forename: H
authors.initials: H
authors.lastname: Saitoh
authors.forename: J
authors.initials: J
authors.lastname: Yodoi
mesh_terms: D000276:Adjuvants, Immunologic / Q000494:pharmacology; D000944:Antigens, Differentiation, B-Lymphocyte / Q000032:analysis / Q000378:metabolism*; D001667:Binding, Competitive; D002458:Cell Fractionation; D002460:Cell Line; D002474:Cell-Free System; D006801:Humans; D007073:Immunoglobulin E / Q000378:metabolism*; D007371:Interferon-gamma / Q000494:pharmacology; D015847:Interleukin-4; D007378:Interleukins / Q000494:pharmacology; D015472:Leukemia, Eosinophilic, Acute / Q000378:metabolism*; D011961:Receptors, Fc / Q000032:analysis / Q000378:metabolism*; D017455:Receptors, IgE; D015375:Receptors, Interleukin-2 / Q000378:metabolism*
chemical_list: D000276:Adjuvants, Immunologic; D000944:Antigens, Differentiation, B-Lymphocyte; D007378:Interleukins; D011961:Receptors, Fc; D017455:Receptors, IgE; D015375:Receptors, Interleukin-2; D015847:Interleukin-4; D007073:Immunoglobulin E; D007371:Interferon-gamma